Iktos Collaborated with Galapagos to Discover Optimised Lead Therapies Using AI Technology
- Under the terms of collaboration, Iktos will use its de novo ligand & structure-based generative modeling technologies & software Makya, planning tool Spaya to speed up the identification of pre-clinical candidates & identify novel chemical matter with appropriate properties
- Iktos has expanded its R&D efforts in the development of an AI technology for retrosynthesis. AI-based retrosynthesis analysis & Spaya enables the systematic exploration & prioritization of synthetic routes for the desired molecule in min.
- Iktos’s AI technology brings new insights & directions into the drug discovery process based on data-driven technology. This technology generates virtual new molecules having all of the characteristics of a therapeutic molecule
Ref: Bussinesswire | Image: Iktos
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.